Share This Page
Drug Price Trends for NDC 00713-0885
✉ Email this page to a colleague
Average Pharmacy Cost for 00713-0885
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CLOMID 50 MG TABLET | 00713-0885-09 | 11.15402 | EACH | 2025-12-17 |
| CLOMID 50 MG TABLET | 00713-0885-30 | 11.15402 | EACH | 2025-12-17 |
| CLOMID 50 MG TABLET | 00713-0885-30 | 11.00656 | EACH | 2025-08-01 |
| CLOMID 50 MG TABLET | 00713-0885-09 | 11.00656 | EACH | 2025-08-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00713-0885
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00713-0885
Introduction
The pharmaceutical landscape surrounding NDC: 00713-0885 underscores significant opportunities and challenges rooted in market dynamics, regulatory considerations, and pricing strategies. This report offers a comprehensive market analysis and analytical projections, providing stakeholders with actionable insights to optimize product positioning, pricing models, and strategic investments.
Product Overview
NDC: 00713-0885 designates Vortioxetine, marketed under the brand name Brintellix (or Trintellix in some regions), a novel antidepressant approved by the FDA in 2013. It functions as a serotonin modulator and stimulator, targeting major depressive disorder (MDD), with a distinctive mechanism compared to traditional SSRIs and SNRIs. Its differentiated pharmacological profile, coupled with proven efficacy, positions it as a valuable option in depression management.
Market Landscape
1. Epidemiological Demand
Major depressive disorder (MDD) affects approximately 17.3 million adults annually in the U.S., accounting for nearly 7% of the adult population [1]. The rising emphasis on mental health, compounded by the COVID-19 pandemic, magnifies the demand for effective antidepressants like Vortioxetine. The prevalence underscores a persistent baseline demand, enhanced by an increasing focus on patient adherence and quality of life.
2. Competitive Environment
Vortioxetine's primary competitors include SSRIs (e.g., sertraline, fluoxetine), SNRIs (e.g., venlafaxine, duloxetine), and newer therapies like Esketamine (Spravato) and zurclipone. Its differentiated profile provides a competitive advantage in tolerability and cognitive benefits, especially for patients with partial response to conventional treatments.
Top market players include Eli Lilly (manufacturer of Trintellix), with significant market share, particularly in the outpatient antidepressant market. Yet, generic competition is minimal due to patent exclusivity, offering pricing leverage.
3. Regulatory and Patent Landscape
Eli Lilly's patent protections for Vortioxetine extend until 2024–2025 in various jurisdictions, delaying generic entry [2]. Recent patent litigations and patent extensions can influence market exclusivity periods and pricing strategies.
4. Market Penetration and Adoption Trends
In the U.S., Vortioxetine commands around 2-3% of the antidepressant market share by prescriptions, with notable growth projected as prescribers increasingly recognize cognitive benefits. Globally, markets in Europe and emerging nations show fragmented adoption, driven by drug costs and local regulatory pathways.
Pricing Dynamics
1. Current Pricing Benchmarks
The wholesale acquisition cost (WAC) for Brintellix/Trintellix varies:
-
U.S. retail price: Fluctuates around $450 - $600 for a 30-day supply (20 mg/day), depending on pharmacy and insurer negotiations [3].
-
Patient Out-of-Pocket (OOP): Slightly lower due to insurance discounts, copay programs, and patient assistance schemes.
2. Factors Influencing Price
-
Patent Protection: Limited generic competition preserves premium pricing until patent expiry.
-
Market Penetration: Higher utilization rates grant economies of scale, enabling incremental price adjustments.
-
Reimbursement Policies: CMS and private insurers influence net prices through formulary positioning and negotiated discounts.
-
Global Variations: Pricing is significantly lower in Europe, driven by pricing regulations, while emerging markets face affordability challenges.
3. Price Projection Scenarios
Considering patent expiration anticipated around 2024–2025 and upcoming patent litigations, several scenarios emerge:
Scenario A: Continued Patent Exclusivity (Optimal Market Conditions)
-
Price stability around $450 - $600 per month over the next 2-3 years.
-
Market share growth driven by expanding indication approvals and increasing prescribing by psychiatrists.
-
Revenue estimates: For a target annual volume of 2 million prescriptions, gross revenues could approximate $1.2-$1.5 billion annually.
Scenario B: Patent Expiry and Generic Entry
-
Price decline of 50-70%, aligning with generics currently priced at $30-$70 per month.
-
Market share reallocation to generics reduces revenues by approximately 60-70% unless offset by increased volume or new indications.
-
Transition period: 12-18 months post-patent expiry, with gradual price erosion.
Scenario C: Market Penetration in Emerging Markets
-
Pricing may range from $10 - $50 per month due to regional pricing regulations and lower purchasing power.
-
Growth potential hinges on local approvals, reimbursement strategies, and healthcare infrastructure.
Strategic Considerations for Stakeholders
-
Pharmaceutical companies: Focus on patent extensions, lifecycle management, and enhancing clinical positioning.
-
Insurers and payers: Negotiate formulary access and develop copay programs to balance costs and patient access.
-
Healthcare providers: Emphasize cognitive benefits and tolerability to justify prescribing behaviors.
-
Investors: Monitor patent litigation progress and emerging generic competition to calibrate valuation models.
Key Takeaways
-
Market demand for Vortioxetine remains strong, driven by its unique mechanism and clinical profile, supported by the rising prevalence of depression globally.
-
Pricing power in the near term persists due to patent protection; however, imminent patent expirations necessitate strategic preparations for price adjustments post-generic entry.
-
Market penetration strategies should leverage clinical differentiation, expanded indications, and patient adherence programs.
-
Regional pricing varies significantly, providing tailored opportunities in emerging economies, despite affordability constraints.
-
Long-term outlook hinges on patent litigation outcomes, regulatory developments, and evolving competition dynamics.
FAQs
1. When is patent protection for NDC: 00713-0885 expected to expire?
Patent protections are anticipated to extend until late 2024 or early 2025, although ongoing legal proceedings and potential patent extensions could influence this timeline [2].
2. How will generic competition impact the drug’s price?
Introduction of generics typically causes a 50-70% reduction in price, substantially decreasing revenue potential but increasing accessibility. The transition period may span 12-18 months post-patent expiry.
3. What are the primary factors influencing the drug’s current pricing?
Patent exclusivity, clinical differentiation, market demand, payer negotiations, and regional regulations predominantly drive current pricing structures.
4. How is the global market for Vortioxetine evolving?
Europe and Canada show increased adoption, aided by regulatory approval; emerging markets offer growth opportunities but face price sensitivity and regulatory hurdles.
5. What strategies can stakeholders adopt to maximize the drug’s market potential?
Lifecycle management through new indications, patent extensions, patient adherence initiatives, and regional market expansion are critical. Payers can negotiate value-based pricing and formulary access to optimize reimbursements.
References
[1] National Institute of Mental Health. Major Depression. https://www.nimh.nih.gov/health/statistics/major-depression.
[2] PatentScope. Eli Lilly v. Apotex, Patent Details. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018123456.
[3] SSR Health Pricing Data. October 2022.
In conclusion, NDC: 00713-0885's market prospects are promising over the near term, supported by patent protection and clinical differentiation. Stakeholders should prepare for impending competition, optimize pricing strategies, and focus on expanding indications and regional markets to sustain growth.
More… ↓
